# Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder

> **NCT01694667** · PHASE2 · COMPLETED · sponsor: **Hugo W. Moser Research Institute at Kennedy Krieger, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Autism Spectrum Disorders
- Hyperactivity

## Interventions

- **DRUG:** Omega-3 Fatty Acids
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01694667
- **Lead sponsor:** Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-12
- **Final completion:** 2013-05
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2020-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01694667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01694667, "Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01694667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*